TORL-1-23 Generates Responses in Heavily Pretreated CLDN6-Positive Solid Tumors

September 15, 2024 9:00 am

by Chris Ryan

TORL-1-23, a Claudin-6 (CLDN6)–targeted antibody-drug conjugate (ADC), led to responses in patients with heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer. Additionally, the agent was well tolerated, according to data from the phase 1 TORL-123-001 … Read more

Dr Angeles Alvarez Secord on “Exciting” Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer

September 15, 2024 9:00 am

by Rose McNulty

Mirvetuximab soravtansine showed promise for patients with heavily pretreated FRα-positive, platinum-sensitive ovarian cancer—a challenging patient population to treat—in the phase 2 PICCOLO trial. New data from the study presented at the European Society for Medical Oncology (ESMO) … Read more

Dato-DXd Shows Promising Efficacy in Endometrial and Ovarian Cancer

September 15, 2024 9:00 am

by Jason M. Broderick

The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 … Read more

Five-year PFS results show advantage for niraparib maintenance in patients with advanced ovarian cancer, with no OS benefit

September 14, 2024 9:00 am

At the ESMO Congress 2024 (Barcelona, 13–17 September), final overall survival (OS) data after a median follow-up of approximately 6 years revealed no benefit of niraparib maintenance over placebo for patients newly diagnosed with advanced ovarian cancer at high risk … Read more

‘Symptom triggered’ testing can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected

August 13, 2024 9:00 am

by University of Birmingham

A study published in the International Journal of Gynecological Cancer found that the UK’s protocol for picking up early-stage disease in women with high grade serous ovarian cancer—the most common, aggressive, and lethal form of the … Read more

Platinum-resistant ovarian cancer: mirvetuximab soravtansine benefits are maintained in patients who require dose modifications

June 20, 2024 9:00 am

As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required Read more

Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers

June 4, 2024 9:00 am

by Wayne Kuznar

CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more

No Benefit to Adding Atezolizumab to Chemo/Bevacizumab for Ovarian Cancer

June 2, 2024 9:00 am

by Silas Inman

The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more

Sister Study Cohorts Shows Association of Gential Talc Use and Ovarian Cancer

May 23, 2024 9:00 am

by Ariana Pelosci

Results of a recent study published in the Journal of Clinical Oncology highlighted the association of ovarian cancer with talcum powder (talc) use.1 The findings were from an extensive analysis of the Sister Study cohort.… Read more

New Approach May Help People with Cancer Better Manage Depression, Pain, and Fatigue

May 14, 2024 9:00 am

Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be Read more

Yoga shows ‘most improvement’ in restoring brain health in long-term cancer survivors, Northeastern researcher says

May 10, 2024 9:00 am

by Cynthia McCormick Hibbert

For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”

newly published study by a Northeastern professor says that yoga might hold the key to … Read more

New FDA Guidance Looks to Improve Clinical Trial Enrollment and Diversity

April 30, 2024 9:00 am

by Sabrina Serani

The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.

While the FDA notes … Read more

Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC

March 22, 2024 9:00 am

By Ryan Scott

Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more

Rezatapopt Shows Preliminary Efficacy in TP53 Y220C–Mutated Advanced Ovarian Cancer

March 19, 2024 9:00 am

By Kristi Rosa

Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more

Ursula Matulonis, MD, on Concordance of CA-125 and Radiographic Progression in Ovarian Cancer

February 21, 2024 9:00 am

By Mark Fuerst

About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more

Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs

— “If the patients are not taking the drug, then it’s not going to work”

February 6, 2024 10:30 am

By Associated Press.

For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.

They’ve ignited a movement to radically change … Read more

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy

January 11, 2024 9:00 am

Clearity offers emotional support to people diagnosed with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personalized, one-to-one assistance with navigating the impact of an ovarian cancer diagnosis, our team of OC Counselors Read more

Trial Analyzing MEK Inhibitor Combo for Ovarian Cancer Subset Begins

December 21, 2023 9:00 am

By Ashley Chan

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more

Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer

December 15, 2023 9:00 am

By Edward Winstead

For people being treated for cancer, participating in virtual mind–body fitness classes may have important benefits, such as reducing the risk of being hospitalized for treatment-related problems, according to results from a clinical trial.

In the trial, … Read more

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

December 6, 2023 9:00 am

By James H. Doroshow, M.D.

More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision

Read more